News

SciSparc Licenses Pain Therapy to Biotech Co. for $6M

SciSparc Licenses Pain Therapy to Biotech Co. for $6M

SciSparc Completes Exclusive License Agreement

SciSparc Ltd. (Nasdaq: SPRC), a specialized clinical-stage pharmaceutical company focused on addressing central nervous system disorders, has announced the successful completion of an Exclusive Patent License Agreement with Polyrizon Ltd. This agreement empowers Polyrizon to develop and sublicense SciSparc's SCI-160 program, which is primarily aimed at pain management solutions.

Overview of the Licensing Agreement

As part of this agreement, SciSparc will receive consideration valued at $3 million in Polyrizon securities. Furthermore, if specific development milestones are achieved, SciSparc could earn milestone payments totaling around $3 million in cash. These terms highlight the significant recognition of SciSparc's proprietary technology within the pain treatment sector.

Composition and Effectiveness of SCI-160

SCI-160 is an advanced synthetic blend of cannabinoids and N-acylethanolamines, specifically targeting pain relief. Previous pre-clinical studies have demonstrated that this combination effectively mediates analgesic effects in the peripheral nervous system while minimizing significant side effects, thus benefiting individuals suffering from both acute and chronic pain.

Comparison with Traditional Pain Management Solutions

Notably, SCI-160 has shown a favorable tolerance profile, with no significant adverse clinical effects reported. Research suggests that its analgesic properties could rival, and in some instances, surpass the potency of high-dose morphine. This is particularly important given the rising public health concerns associated with prescription opioid abuse.

Significance of the License Agreement

Granting global rights for the SCI-160 program to Polyrizon represents a strategic decision for SciSparc. With Polyrizon's expertise and resources in drug development, this partnership aims to accelerate the commercialization of SCI-160, ultimately enhancing the availability of effective pain management options.

About SciSparc Ltd.

SciSparc Ltd. is an innovative clinical-stage pharmaceutical company that focuses on developing cannabinoid-based therapies. Their portfolio features several promising drug development programs, including SCI-110 for treating Tourette Syndrome and Alzheimer's disease, SCI-160 for pain management, and SCI-210 for addressing autism and status epilepticus. Additionally, the company holds a controlling interest in a subsidiary that markets hemp seed oil-based products on various popular platforms.

Importance of Ongoing Research

As cannabinoids gain increased recognition for their therapeutic potential, continuous research and development are crucial. SciSparc's commitment to developing cannabinoid pharmaceuticals positions the company advantageously in the evolving landscape of pain management therapies, reflecting their dedication to enhancing patient outcomes.

Future Opportunities

With the finalization of this license agreement, SciSparc is poised to explore additional collaborations, potential revenue opportunities, and the advancement of innovative treatments in pain management. The company’s leadership team, including CEO and CFO Mr. Oz Adler, is committed to guiding SciSparc towards pioneering solutions that address unmet medical needs.

Frequently Asked Questions

What is the SCI-160 program?

SCI-160 is a proprietary pain therapy product developed by SciSparc, utilizing cannabinoids and N-acylethanolamines.

How much is the licensing deal worth?

The licensing agreement with Polyrizon is valued at up to $6 million, which includes $3 million in securities and potential milestone payments.

What conditions does SCI-160 aim to treat?

SCI-160 is designed to address various pain conditions, focusing on providing relief for both acute and chronic pain.

Who is SciSparc Ltd.?

SciSparc Ltd. (Nasdaq: SPRC) is a clinical-stage pharmaceutical company dedicated to developing cannabinoid-based therapies for mental health and central nervous system disorders.

How does SCI-160 compare to opioids?

SCI-160 has demonstrated comparable analgesic effects to high-dose morphine, without the significant risk of adverse effects that are often associated with opioids.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BIBIBOP Brings Good Vibes with OLIPOP Happy Hour

Updated Category News Views 175

Boosting Midday Energy with BIBIBOP's New Promo Here we go, folks. BIBIBOP Asian Grill is dialing up the culinary energy just when you need it most. From November 16 to 22, during their Good Energy Happy Hour, they’re serving up a deal designed to pump some pep into your afternoon—free OLIPOP prebiotic soda with any regular bowl purchase. Just stroll into any of their...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 108

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Chime Joins S&P MidCap 400 Amid Merger Jostle

Updated Category News Views 194

Index Shake-Up: Who's In, Who's Out? Hold onto your hats, folks—big changes are coming to the S&P MidCap 400! Chime Financial Inc. is crashing the party, taking a seat at the table, as NorthWestern Energy Group gets the boot. Now, if that doesn’t grab your attention, I don’t know what will. You've got to appreciate the chaos and opportunities that come with a roster...

Continue Reading
WhiteHorse Set to Redeem Its 2028 Notes Completely

Updated Category News Views 104

WhiteHorse Finance Divests Its 7.875% Notes Well, WhiteHorse Finance is making some moves, folks. They're planning to redeem their 7.875% notes due in 2028, totaling a cool $34.5 million. This ain't just pocket change, especially with the way markets have been bobbing and weaving lately. The redemption is slated for December 15, 2026, when the notes will get delisted from...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 201

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 194

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
IEHP's Wellness Center Launch Faces Delay in California

Updated Category News Views 104

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

Continue Reading
55 Broad Street's New Face: A $500M Revamp with RXR

Updated Category News Views 189

Recapitalization: Changing the Game for 55 Broad Street Here we are again, watching yet another iconic Manhattan building redefine itself. This time, it's 55 Broad Street's turn, as Silverstein, MetroLoft, and RXR shake things up. Newmark Group, Inc. (NASDAQ: NMRK), the fiery real estate power player, orchestrated a dynamic transaction involving a $305 million financing...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 120

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 154

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading

Top 5 Most Recently Viewed Articles

Pudu Robotics Introduces Next-Gen FlashBot for Smarter Delivery

Updated Category News Views 175

Pudu Robotics Launches Advanced FlashBot for Modern Delivery Needs Pudu Robotics, a pioneer in service robotics, has unveiled the upgraded version of its building delivery robot, FlashBot. This new iteration promises to enhance delivery services across various environments, catering to hotels, office buildings, healthcare facilities, and more. The company is focused on...

Continue Reading
Compass Diversified Holdings Faces Class Action Lawsuit

Updated Category News Views 208

Compass Diversified Holdings Class Action Overview Pomerantz LLP has announced the initiation of a class action lawsuit against Compass Diversified Holdings (CODI or the Company) for concerns surrounding securities fraud and unlawful business practices. Investors who have experienced losses due to the company’s actions are urged to take note and consider joining the...

Continue Reading
Celebrating 10 Years of Monsterverse: Iconic Collectibles Unveiled

Updated Category News Views 291

Celebrating a Decade of the Monsterverse In a remarkable celebration of cinematic history, Legendary Entertainment and Mondo have come together to mark the 10th anniversary of the Monsterverse. This expansive universe has brought to life some of the most iconic monsters, including the legendary Godzilla and King Kong. This collaboration represents a thrilling opportunity...

Continue Reading
Central Iron Ore Limited Advances British King Gold Project

Updated Category News Views 286

Central Iron Ore Limited's Latest Developments Vancouver, British Columbia – Central Iron Ore Limited (CIO – TSX.V) is excited to share that it has successfully submitted a National Instrument 43-101 Technical Report detailing an updated Mineral Resource Estimate for its British King Gold Project. Highlights of the Technical Report The newly submitted technical...

Continue Reading
Insights on Grocery Outlet Holding's Recent Insider Activity

Updated Category News Views 208

Recent Insider Selling at Grocery Outlet Holding In a notable insider transaction, Steven Wilson, the Executive Vice President of Grocery Outlet Holding, sold shares amounting to $73,449. The sale involved 6,477 shares, as documented in an SEC filing. Such insider movements often catch the attention of investors as they can reflect the insider's confidence in the...

Continue Reading